BUSINESSDAILY MAIL
AstraZeneca holds talks with Bristol Myers Squibb over £300bn merger
AstraZeneca is holding discussions with Bristol Myers Squibb regarding a potential £300 billion merger. The talks could result in a major business consolidation between the two companies.
Related Signal
Adjacent reporting
- AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
- AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
- AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
- AstraZeneca said to have explored Bristol Myers merger
- AstraZeneca Said to Have Explored Bristol Myers Merger
- AstraZeneca Is Said to Have Explored Bristol Myers Merger